Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to US Patent 7,132,570 (the “570 patent”) for Teva’s wakefulness product, Nuvigil (armodafinil) tablets.
Subscribe to our email newsletter
These settlements dismiss a pending appeal with the US Court of Appeals for the Federal Circuit of a trial court decision that found the ‘570 patent to be valid and infringed.
Teva has reached settlements with each of these companies, granting licenses to allow these parties to market their generic products 180 days after Mylan, the first generic company to file an abbreviated new drug application (ANDA) for the 50mg, 150mg, and 250mg dosages of Nuvigil.
The settlements allow Actavis to launch generic 100mg and 200mg dosages in June 2016, and the others may launch these dosages 180 days after Actavis in the 100mg and 200mg dosage forms. Additional terms of the settlements are agreed by the parties to remain undisclosed.
Previously, Teva settled its patent infringement litigation regarding the ‘570 patent against Mylan, which allowed Mylan to begin selling generic versions of 50mg, 150mg, and 250mg Nuvigil under license beginning in June 2016, or earlier under certain circumstances.